SEC Form 4 · accession 0001171843-16-011941
IMMUNOMEDICS INC · IMMU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary E Paetzold
Director
Period of report
Aug 23, 2016
Accepted (ET)
Aug 25, 2016 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000722830
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 23, 2016 | M | 15,000 | $1.96 | A | 82,474 | D | |
| Common StockF1,F2 | Aug 23, 2016 | S | 15,000 | $2.9782 | D | 67,474 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F3 | $1.96 | Aug 23, 2016 | M | 15,000 | D | — | Aug 24, 2016 | Common Stock, par value $0.01 per share | 15,000 | 0 | D |
Explanation of responses
- F1The price in column 4 is a weighted average price. The prices actually received by the reporting person in this transaction range from $2.92 to $3.03.
- F2The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range reported.
- F3The stock options were granted pursuant to the Immunomedics, Inc. 2002 Stock Option Plan and vested over four years at a rate of 25% per year.